# 腺相关病毒Aav载体基因治疗市场 > 腺病毒相关病毒（AAV）载体基因治疗市场研究报告 按疾病类型（血液恶性肿瘤、神经系统疾病、心血管疾病、眼科疾病、肿瘤学）、按载体血清型（AAV1、AAV2、AAV5、AAV6、AAV8、AAV9）、按给药途径（静脉注射、肌肉注射、皮下注射、眼内注射、脑内注射）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年 - **Forecast Period:** 2025 - 2035 - **CAGR:** 25.68% - **2024:** $ 5.72 Billion - **2025:** $ 7.19 Billion - **2035:** $ 70.67 Billion - **Key Players:** Spark Therapeutics (US), Bayer AG (DE), Novartis AG (CH), Bristol-Myers Squibb (US), GSK (GB), Pfizer Inc. (US), Sarepta Therapeutics (US), Astellas Pharma Inc. (JP), UniQure N.V. (NL) **Report ID:** MRFR/HC/27946-HCR · **Pages:** 128 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/adeno-associated-virus-aav-vector-based-gene-therapy-market-29672 --- ## Market Summary ## **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Overview** As per MRFR analysis, the Adeno-associated Virus Vector-based Gene Therapy Market Size was estimated at 5.72 (USD Billion) in 2024. The Adeno-associated Virus Vector-based Gene Therapy Market Industry is expected to grow from 7.19 (USD Billion) in 2025 to 56.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 25.68% during the forecast period (2025 - 2034). Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Key Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Trends Highlighted** Increasing prevalence of genetic disorders The growing incidence of genetic diseases, such as cystic fibrosis, sickle cell anemia, and hemophilia, is driving the demand for innovative gene therapy treatments. Advancements in vector technology AAV vectors have gained popularity due to their safety profile, low immunogenicity, and ability to deliver genes to specific tissues. Ongoing improvements in vector design and delivery methods further enhance their therapeutic potential. Expanding the range of therapeutic applications AAV vector-based gene therapy holds promise for treating a wide range of diseases, including neurological disorders, cardiovascular diseases, ophthalmic diseases, and infectious diseases. Research is ongoing to explore new targets and expand the therapeutic reach. Emerging gene editing technologies The advent of technologies like CRISPR-Cas9 enables precise genome editing, offering potential synergies with AAV vectors for more targeted and effective gene therapies. Personalized and tailored therapies As the genetic basis of diseases becomes better understood, personalized gene therapies can be tailored to individual patient profiles, improving treatment outcomes and reducing adverse effects.  collaborations and partnerships Strategic collaborations between pharmaceutical companies, academia, and patient advocacy groups facilitate research, development, and access to AAV vector-based gene therapies. Investments in clinical trials Numerous clinical trials are underway, evaluating the efficacy and safety of AAV vector-based gene therapies for a range of diseases. Regulatory approvals Several AAV vector-based gene therapies have received regulatory approval in recent years, further validating their clinical potential and driving market growth.Patient advocacy and awareness Strong patient advocacy and increasing awareness about genetic disorders contribute to increased demand for gene therapy treatments. ## **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Drivers** ### **Growing Prevalence of Genetic Disorders** The rising incidence of genetic disorders worldwide is a significant driver of the  Adeno-associated Virus (AAV) Vector-based Gene Therapy Market. As per a report by the World Health Organization (WHO), genetic disorders affect approximately 6-8% of the population. This increase in prevalence is attributed to factors such as consanguineous marriages, environmental pollution, and unhealthy lifestyles. The demand for AAV-based gene therapies is growing as a result of the need for effective treatments for these disorders. ### **Advancements in Gene Editing Technologies** The continuous advancements in gene editing technologies, such as CRISPR-Cas9 and TALENs, have revolutionized the field of gene therapy. These technologies allow for precise and efficient editing of the genome, making AAV-based gene therapies more feasible and promising. Researchers are now able to target specific genetic defects and correct them, offering hope for the treatment of various diseases. ### **Government Support and Funding** Government agencies and organizations worldwide are recognizing the potential of AAV-based gene therapies and providing substantial funding for research and development. This support is crucial for the advancement of these therapies and their eventual commercialization. Funding from government grants and initiatives enables researchers to conduct clinical trials, evaluate safety and efficacy, and accelerate the development process. ## **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Segment Insights** ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Disease Type Insights** The Adeno Associated Virus (AAV) Vector Based Gene Therapy Market is segmented by Disease Type into Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, and Oncology. Among these, the [Oncology](../../../reports/oncology-information-systems-market-7080) segment held the largest market share of around 42.9% in 2023 and is expected to continue its dominance throughout the forecast period. The high prevalence of cancer and the increasing adoption of gene therapy for cancer treatment contribute to the significant share of this segment. The Hematological Malignancies segment is also expected to witness substantial growth during the forecast period, owing to the rising incidence of blood cancers and the development of novel gene therapies for hematological malignancies. The increasing research and development activities in the field of gene therapy for neurological disorders are expected to drive the growth of the Neurological Disorders segment. The Cardiovascular Diseases segment is anticipated to experience steady growth due to the increasing prevalence of cardiovascular diseases and the potential of gene therapy to address unmet medical needs in this area. The Ophthalmic Diseases segment is expected to grow at a moderate pace, driven by the growing demand for gene therapy for inherited retinal diseases and other ophthalmic conditions. Overall, the Disease Type segment of the  Adeno Associated Virus (AAV) Vector Based Gene Therapy Market offers significant growth opportunities for market players due to the rising prevalence of chronic diseases, the increasing demand for personalized medicine, and the continuous advancements in gene therapy technology. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Vector Serotype Insights** The Vector Serotype segment plays a critical role in the  Adeno Associated Virus (AAV) Vector Based Gene Therapy Market. Key serotypes include AAV1, AAV2, AAV5, AAV6, AAV8, and AAV9. Each serotype exhibits unique tropism and transduction efficiency in different target tissues. For instance, AAV1 and AAV6 show preferential transduction in the central nervous system, while AAV2 and AAV5 are more effective in the liver and skeletal muscle, respectively. Market data indicates that AAV8 and AAV9 have gained significant traction due to their broad tropism and reduced immunogenicity. The versatility of AAV serotypes enables researchers to tailor gene therapies to specific diseases and tissues, driving the growth of the AAV Vector-Based Gene Therapy Market. The increasing prevalence of genetic disorders, the development of novel gene therapies, and the expansion of clinical trials contribute to the growing demand for AAV vectors. ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Administration Route Insights** Intravenous administration dominated the  Adeno-associated Virus (AAV) Vector-based Gene Therapy Market in 2023, accounting for over 45% of the market revenue. This dominance is attributed to the ease of administration and widespread use of intravenous delivery for systemic gene therapy applications. Intramuscular administration is another significant route, particularly for local or targeted gene delivery, and is expected to witness steady growth over the forecast period. Subcutaneous administration offers advantages in terms of sustained drug release and reduced systemic exposure, making it suitable for certain gene therapies. Intraocular administration is gaining traction for gene therapies targeting eye disorders, while intracerebral administration is primarily used for gene therapies targeting neurological disorders. The Adeno-associated Virus (AAV) Vector-based Gene Therapy Market is expected to continue to evolve, with advancements in delivery technologies and the development of new gene therapies driving growth across various administration routes. ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Regional Insights** Regionally, North America is anticipated to dominate the market, capturing a significant market share due to the rising prevalence of genetic disorders, the presence of major pharmaceutical companies, and supportive government initiatives. Europe is projected to follow North America, driven by increasing healthcare expenditure, a growing focus on personalized medicine, and the availability of skilled professionals. The APAC region is expected to witness substantial growth attributed to rising healthcare awareness, increasing disposable income, and government investments in healthcare infrastructure. South America and MEA are expected to contribute to the market growth, although at a slower pace compared to other regions. Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Key Players and Competitive Insights** Major players in the Adeno-associated Virus (AAV) Vector-based Gene Therapy Market are continuously striving to develop innovative products and expand their market presence. Strategic collaborations and partnerships with other companies are common, allowing access to new technologies, resources, and markets. Leading Adeno-associated Virus (AAV) Vector-based Gene Therapy Market players invest heavily in research and development to stay competitive and bring new therapies to market. Intense competition drives ongoing market development, with a focus on improving treatment efficacy, safety, and patient outcomes. The competitive landscape is expected to remain dynamic in the coming years. Among the leading players in the Adeno-associated Virus (AAV) Vector-based Gene Therapy Market, Biogen stands out as a leader. The company has a strong portfolio of gene therapies for treating genetic diseases, including its approved product, Zolgensma, for spinal muscular atrophy. Biogen's extensive pipeline of gene therapy candidates targets various neurological, neuromuscular, and metabolic disorders. With a strong focus on patient-centric innovation, Biogen is well-positioned to continue its dominance in the market. A significant competitor in the Adeno-associated Virus (AAV) Vector-based Gene Therapy Market is Novartis. The company has been actively involved in gene therapy research and development for several years. Novartis's Zolgensma, a gene therapy for spinal muscular atrophy, is the first approved treatment of its kind. In addition to spinal muscular atrophy, Novartis is developing gene therapies for other diseases, including hemophilia, sickle cell disease, and inherited retinal diseases. The company's commitment to innovation and its strong research capabilities make it a formidable competitor in the market. **Key Companies in the Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Include** - uniQure - Lysogene - AveXis - **[Sangamo Therapeutics](https://www.sangamo.com/science/technology-platforms/delivery-platform/)** - Dimension Therapeutics - Regenxbio - Bluebird Bio - Audentes Therapeutics - Spark Therapeutics - Oxford BioMedica - Urogen Pharma - Solid Biosciences - ReNeuron - Voyager Therapeutics - Nightstar Therapeutics ## **Adeno Associated Virus Aav Vector Based Gene Therapy Market Industry Developments** - **Q4 2024: First brain-delivered AAV therapy approved by FDA** On November 13, 2024, the FDA approved PTC Therapeutics' Kebilidi (eladocagene exuparvovec-tneq), the first adeno-associated virus (AAV) gene therapy delivered directly into the brain, for the treatment of AADC deficiency in children and adults. This marks a significant regulatory milestone for AAV-based gene therapies targeting the central nervous system. ## **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Segmentation Insights** ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Disease Type Outlook** - Hematological Malignancies - Neurological Disorders - Cardiovascular Diseases - Ophthalmic Diseases - Oncology ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Vector Serotype Outlook** - AAV1 - AAV2 - AAV5 - AAV6 - AAV8 - AAV9 ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Administration Route Outlook** - Intravenous - Intramuscular - Subcutaneous - Intraocular - Intracerebral ### **Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Regional Outlook** - North America - Europe - South America - Asia Pacific - Middle East and Afrca ## Market Drivers ### 生物制药投资增长 生物制药行业投资的激增是腺病毒相关病毒（AAV）载体基因治疗市场的重要驱动力。随着制药公司和风险投资家越来越多地将资金投入基因治疗研究，基于AAV的疗法开发正获得动力。报告显示，生物制药市场预计将显著增长，预测表明其价值可能超过数千亿。这一资金的涌入不仅加速了研究和开发，还增强了学术机构与行业参与者之间的合作，促进了AAV载体技术的创新。这种动态可能导致新疗法的推出，进一步刺激市场增长。 ### 基因治疗的监管支持 监管机构越来越多地支持基因疗法的开发和批准，这成为腺病毒相关病毒（AAV）载体基因疗法市场的重要推动力。旨在加快基因疗法审查过程的举措变得越来越普遍，机构实施的框架促进了对创新治疗的更快获取。这种监管环境鼓励公司投资于AAV载体技术，因为市场路径变得更加清晰和高效。近年来多个AAV基础疗法的批准突显了这一趋势，表明市场未来发展的有利前景。 ### 基因编辑技术的进展 基因编辑技术的进步正在显著影响腺相关病毒（AAV）载体基因治疗市场。CRISPR和TALEN等创新提高了基因修饰的精确性和效率，与AAV载体形成了协同效应。这些技术使研究人员能够开发出更有效的疗法，能够针对特定的基因突变。基因编辑市场预计将达到可观的数字，估计在未来几年可能超过数十亿美元。基因编辑与AAV载体技术的交汇点可能会促进新疗法的发展，从而扩大市场并吸引投资。 ### 遗传疾病的发病率上升 遗传疾病的发病率不断上升是腺病毒相关病毒（AAV）载体基因治疗市场的主要驱动力。随着越来越多的人被诊断出患有血友病、肌营养不良和囊性纤维化等疾病，对有效基因治疗的需求也在上升。根据最近的估计，遗传疾病影响大约每300个出生中就有1个，突显出需要创新治疗的庞大患者群体。这种日益增长的流行病率需要开发针对性的治疗，而AAV载体正好适合提供这种治疗。AAV载体有效地将治疗基因传递到目标细胞的能力使其成为解决这些疾病的有前景的解决方案，从而推动市场增长。 ### 对基因疗法的认识和接受度提高 日益增长的医疗专业人员和患者对基因疗法的认识和接受度是腺病毒相关病毒（AAV）载体基因疗法市场的关键驱动因素。随着教育倡议和成功案例的出现，基因疗法的认知正在积极转变。调查显示，越来越多的医疗提供者现在更倾向于推荐基因疗法，反映出对这些创新治疗的更广泛接受。这一转变可能会增强患者对AAV基因疗法的需求，因为个人对其选择变得更加了解。因此，这种接受度的提高可能会导致更高的采用率，进一步推动市场增长。 ## Future Outlook 腺病毒相关病毒（AAV）载体基因治疗市场预计将在2024年至2035年间以25.68%的年均增长率增长，推动因素包括基因编辑技术的进步和遗传疾病的日益普遍。 **New opportunities:** - 为罕见疾病开发个性化的AAV载体疗法。 扩大AAV生产能力以满足日益增长的需求。 与生物技术公司建立战略合作伙伴关系，以推动创新的AAV应用。 到2035年，基于AAV载体的基因治疗市场预计将会强劲而充满活力。 ## Segment Insights ### 按疾病类型：肿瘤学（最大）与神经系统疾病（增长最快） 腺病毒相关病毒（AAV）载体基因治疗市场在各种疾病类型中展现出多样化的应用。其中，肿瘤学成为最大的细分市场，因其对创新疗法的迫切需求而备受关注。血液恶性肿瘤、心血管疾病和眼科疾病也对整体市场有所贡献，但与肿瘤学和神经系统疾病相比，其份额相对较小。市场份额的分布突显了对需要有效和新颖治疗方案的关键病症的战略关注。AAV载体基因治疗市场的增长趋势主要受到基因编辑技术进步和治疗应用管道增加的推动。神经系统疾病被认定为增长最快的细分市场，反映出针对阿尔茨海默病和帕金森病等复杂病症的研究努力激增。患者人数的增加、未满足的医疗需求以及有效基因治疗的潜力等因素显著推动了这一增长。随着创新的不断推进，AAV基因治疗的市场轨迹依然乐观，应用范围在各种疾病中不断扩大。 肿瘤学：主导与神经系统疾病：新兴 肿瘤学在基于AAV载体的基因治疗市场中占据主导地位，反映出对靶向和有效癌症治疗的强劲需求。癌症类型的普遍性以及对创新疗法的迫切需求推动了该领域的重大投资。AAV载体为肿瘤细胞中的基因传递提供了有前景的策略，增强了治疗效果，同时最小化副作用。相比之下，神经系统疾病代表了新兴领域，展现出快速增长和日益增加的研究关注。像ALS和亨廷顿病这样的疾病的复杂性为AAV疗法带来了挑战和机遇。对这些疾病的遗传基础进行修改的潜力正在获得动力，从而吸引了研究人员和投资者的关注，旨在探索变革性的治疗解决方案。 ### 按载体血清型：AAV9（最大）与AAV2（增长最快） 在腺病毒相关病毒（AAV）载体基础的基因治疗市场中，AAV9作为最大的细分市场脱颖而出，因其在基因传递中的强大功效而占据了显著份额。AAV2紧随其后，凭借其独特的特性在多种治疗应用中展现出显著的市场增长。各类血清型的分布表明，尽管AAV9仍然占主导地位，但AAV2的日益采用反映了其在新型基因治疗项目中的潜力。近期趋势显示，强烈强调利用AAV2进行创新应用，特别是在中枢神经系统疾病和肌肉退化方面。随着基因治疗领域的研究与开发持续蓬勃发展，向优化载体安全性和传递系统的转变使AAV2走到前沿，成为新兴疗法的一个有吸引力的选择。越来越多的临床试验突显AAV2的优势，预计将进一步加速其在市场上的采用。 AAV9（主导型）与 AAV2（新兴型） AAV9被认为是AAV载体市场的主导血清型，以其卓越的转导效率而闻名，特别是在非分裂细胞中，使其成为包括神经肌肉和眼科疾病在内的各种治疗领域的理想选择。其在临床应用中的良好记录使AAV9成为基因治疗开发者的首选。另一方面，AAV2由于其多功能性和适合在多种组织中传递基因，特别是在神经应用中的适用性，正在成为一个引人注目的选择。其穿透血脑屏障的能力增强了其治疗潜力，从而吸引了研究人员和临床医生的重大关注，他们希望利用其在新型基因治疗中的能力。 ### 通过给药途径：静脉注射（最大）与肌肉注射（增长最快） 在腺病毒相关病毒（AAV）载体基因治疗市场中，不同给药途径的市场份额分布显示出静脉注射方法的主导地位，这主要归因于其广泛的接受度和对系统性治疗的有效性。另一方面，尽管肌肉注射途径目前的市场份额较小，但由于注射技术的进步、患者依从性以及其在局部治疗中的有效性，正在迅速增长并受到越来越多的青睐。 静脉注射（主导）与肌肉注射（新兴） 静脉给药途径仍然是AAV载体基因治疗领域的主导力量，能够迅速有效地将治疗药物分布到全身。这种方法特别受到青睐，因为它能够输送大量的病毒载体，确保足够的吸收和生物利用度。相反，肌肉注射途径作为一种令人兴奋的替代方案，因其简单性和对专业医疗设施的需求减少而逐渐受到关注。配方和给药技术的创新正在推动其发展，使其成为局部治疗的首选，同时将患者舒适度放在首位。 ## Regional Market Share Analysis 在区域上，北美预计将主导市场，因遗传疾病的日益普遍、主要制药公司的存在以及政府的支持性举措而占据显著的市场份额。 欧洲预计将紧随北美，受医疗支出增加、对个性化医疗的日益关注以及熟练专业人员的可用性推动。亚太地区预计将见证显著增长，归因于医疗意识的提高、可支配收入的增加以及政府对医疗基础设施的投资。 南美和中东非洲预计将对市场增长作出贡献，尽管增速较其他地区缓慢。 来源：初级研究，次级研究，_市场研究未来_数据库和分析师评审 ## Competitive Benchmarking 腺病毒相关病毒（AAV）载体基因治疗市场的主要参与者不断努力开发创新产品并扩大市场影响力。与其他公司的战略合作和伙伴关系很常见，这使得他们能够接触到新技术、资源和市场。 领先的腺病毒相关病毒（AAV）载体基因治疗市场参与者在研发方面投入巨资，以保持竞争力并将新疗法推向市场。激烈的竞争推动了市场的持续发展，重点在于提高治疗的有效性、安全性和患者的治疗结果。预计未来几年竞争格局将保持动态。 在腺病毒相关病毒（AAV）载体基因治疗市场的领先参与者中，Biogen脱颖而出，成为行业领导者。该公司拥有强大的基因治疗产品组合，用于治疗遗传疾病，包括其批准的产品Zolgensma，用于脊髓性肌萎缩症。 Biogen广泛的基因治疗候选药物管线针对各种神经系统、神经肌肉和代谢疾病。凭借对以患者为中心的创新的强烈关注，Biogen在市场上处于有利地位，能够继续保持其主导地位。 在腺病毒相关病毒（AAV）载体基因治疗市场中，Novartis是一个重要的竞争者。该公司在基因治疗的研究和开发方面积极参与已有多年。Novartis的Zolgensma是一种用于脊髓性肌萎缩症的基因治疗，是首个获得批准的此类治疗。 除了脊髓性肌萎缩症，Novartis还在开发针对其他疾病的基因治疗，包括血友病、镰状细胞病和遗传性视网膜疾病。该公司对创新的承诺及其强大的研究能力使其成为市场上一个强大的竞争者。 ## Recent News & Developments - **2024年第四季度：首个由大脑递送的AAV疗法获得FDA批准** 2024年11月13日，FDA批准了PTC Therapeutics的Kebilidi（eladocagene exuparvovec-tneq），这是首个直接递送到大脑的腺相关病毒（AAV）基因疗法，用于治疗儿童和成人的AADC缺乏症。这标志着针对中枢神经系统的AAV基因疗法的一个重要监管里程碑。 ## Report Scope | 2024年市场规模 | 57.18（十亿美元） | | --- | --- | | 2025年市场规模 | 71.86（十亿美元） | | 2035年市场规模 | 706.7（十亿美元） | | 复合年增长率（CAGR） | 25.68%（2024 - 2035） | | 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 | | 基准年 | 2024 | | 市场预测期 | 2025 - 2035 | | 历史数据 | 2019 - 2024 | | 市场预测单位 | 十亿美元 | | 关键公司简介 | 市场分析进行中 | | 覆盖的细分市场 | 市场细分分析进行中 | | 关键市场机会 | 靶向递送系统的进步提高了腺病毒（AAV）载体基因治疗市场的疗效。 | | 关键市场动态 | 对创新疗法的需求上升推动了腺病毒载体基因治疗市场的竞争和监管审查。 | | 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 | ## Frequently Asked Questions **Q: 腺病毒相关病毒（AAV）载体基因治疗市场的当前估值是多少？** A: 2024年市场估值为57.18亿美元。 **Q: 到2035年，AAV载体基因治疗市场的预计市场规模是多少？** A: 2035年的预计估值为706.7亿美元。 **Q: 在预测期内，AAV载体基因治疗市场的预期CAGR是多少？** A: 预计市场在2025年至2035年期间的年均增长率（CAGR）为25.68%。 **Q: 在AAV载体基因治疗市场中，哪些疾病类型处于领先地位？** A: 血液恶性肿瘤和神经系统疾病位居前列，估值分别为180亿美元和150亿美元。 **Q: AAV载体基因治疗市场中的关键载体血清型是什么？** A: AAV8 和 AAV2 是关键的血清型，预计估值分别为 180 亿和 150 亿美元。 **Q: 给药途径如何影响基于AAV载体的基因治疗市场？** A: 静脉给药预计将以180亿美元的估值领先。 **Q: AAV载体基因治疗市场的主要参与者是谁？** A: 主要参与者包括Spark Therapeutics、拜耳公司、诺华公司和百时美施贵宝。 **Q: 在AAV载体基因治疗市场中，肿瘤学的市场表现如何？** A: 肿瘤学预计将达到156.7亿美元的估值。 **Q: 在AAV载体基因治疗市场中，不同疾病类型的预计增长率如何变化？** A: 血液恶性肿瘤和神经系统疾病显示出最高的增长潜力，表明市场动态强劲。 **Q: 增长预测对AAV载体基因治疗市场的投资有什么影响？** A: 预计的显著增长表明了一个有利的投资环境，特别是对于领先公司。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/adeno-associated-virus-aav-vector-based-gene-therapy-market-29672*